RxDoctor Payments Data
★ My doctorsLook up a doctor →

Taisei Kobayashi, MD

Interventional Cardiology · Philadelphia, PANPI 1992936306

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (52.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Boston Scientific at 53.5% of the total. 2025 is the largest year on record at $269,329, more than ten times the $1,247 reported in 2019. Among interventional cardiology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$383,602in general payments, 2019–2025

Across 423 payments — averaging $906.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$205K
  • Medtronic$162K
  • Recor Medical Inc$10K
  • Endovascular Engineering Inc.$4K
  • Edwards Lifesciences$551
  • Abiomed$359
  • plus $1K from 12 others
$90,766in research payments, 2019–2025

Across 54 payments — averaging $1680.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Inari Medical, Inc.$64K
  • Endovascular Engineering Inc.$26K
  • Medtronic$1K

What the payments were for

  • Consulting fees$63,92517%
  • Speaking & faculty fees$89,14123%
  • Travel & lodging$21,4386%
  • Food & beverage$8,8322%
  • Other$200,26652%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific13$205,213
Medtronic(2 entities)345$162,250
Recor Medical Inc4$9,688
Endovascular Engineering Inc.5$4,283
Edwards Lifesciences9$551
Abiomed11$359
Shockwave Medical, Inc10$238
Inari Medical, Inc.3$204
Philips North America LLC3$139
Siemens Medical Solutions USA, Inc.1$120
AstraZeneca2$111
W. L. Gore & Associates, Inc.3$103
Stryker2$83
Penumbra, Inc.3$70
Teleflex LLC3$59
Abbott2$51
Cathworks, Inc.2$41
Cardinal Health 200 LLC2$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$383,602 in reported general payments places this provider in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$61,376
Medicare patients
156
Services billed
454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium11$226

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Philadelphia

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →